Catalysts
MIRM Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
MIRMMirum Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum54
- Value57
- Quality52
- Risk resilience51
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 54/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 33.90%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | — | -$0.49 | -$0.87 | -78.7% | $178.08M | $185.72M |
| Aug 5, 2026 | — | -$0.74 | -$1.06 | -42.8% | $166.33M | $176.2M |
| May 6, 2026 | — | -$0.40 | -$13.43 | -3257.5% | $148.21M | $159.9M |
| Feb 25, 2026 | — | $0.02 | -$0.11 | -650.0% | $142.5M | $148.93M |
| Nov 4, 2025 | — | -$0.10 | $0.05 | +150.0% | $140.88M | $133.01M |
| Aug 6, 2025 | — | -$0.31 | -$0.12 | +61.3% | $130.11M | $127.79M |
| May 7, 2025 | — | -$0.39 | -$0.30 | +23.1% | $98.4M | $111.59M |
| Feb 26, 2025 | — | -$0.27 | -$0.49 | -81.5% | $96.64M | $99.41M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -64.15% and +5.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Related Links
MIRM Catalysts FAQ
What are the next catalysts for MIRM stock?
MIRM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move MIRM stock?
Upcoming events that could move MIRM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could MIRM's next earnings report affect the stock?
MIRM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive MIRM stock higher?
MIRM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt MIRM stock?
MIRM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.